GLP-1s Over 65: What the Data Actually Shows

There is no age at which a GLP-1 drug becomes off-limits, and the labels do not set one. But “allowed” and “the same” are not the same thing, and after 65 the calculation genuinely does shift: toward function and muscle, toward tolerability, and toward whether Medicare will pay.

Here is what the evidence and the labels actually say.

This is general health information, not medical advice. Where it describes how these drugs are used, it is summarizing the FDA-approved prescribing information, not giving instructions; follow your own prescription and your own provider. Any decision about starting, continuing or stopping one of these medicines belongs with a healthcare provider who knows your health history.

Labels read directly and verified September 14, 2026: Wegovy revised 06/2026, Ozempic revised 05/2026, Zepbound revised 8/2026, Mounjaro revised 8/2026.

What do the labels say about age?

Every one of the four major US labels addresses older adults, and none of them impose a limit or a dose change [1][2][3].

The Ozempic label reports that across the pooled glycemic control trials, 744 Ozempic-treated patients (23.6 percent) were 65 or older and 102 (3.2 percent) were 75 or older; in SUSTAIN 6, the cardiovascular outcomes trial, 788 (48 percent) were 65 or older and 157 (9.6 percent) were 75 or older [2]. It concludes: “No overall differences in safety or efficacy were detected between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out” [2].

The Zepbound label states: “No overall differences in safety or effectiveness of ZEPBOUND have been observed between patients 65 years of age and older and younger adult patients” [3]. Mounjaro says the same [4].

The Wegovy label is the most informative, and it is where the one real age-specific caution lives.

The fracture line in the Wegovy label

Section 8.5 of the Wegovy label lays out who was in the trials [1]:

• In the weight-management trials: 233 Wegovy-treated patients (9 percent) were aged 65 to under 75, and 23 (1 percent) were 75 or older.
• In the cardiovascular outcomes trial: 2,656 (30 percent) were aged 65 to 75, and 703 (8 percent) were 75 or older.
• In the MASH liver trial: 138 of 534 (26 percent) were 65 or older, and 13 (2 percent) were 75 or older.

Then it adds two observations [1]:

“In the CV outcomes trial, patients aged 75 years and older reported more hip and pelvis fractures in the WEGOVY injection-treated patients than placebo-treated patients.”

“Patients aged 75 years and older (WEGOVY injection-treated and placebo-treated) reported more serious adverse reactions overall compared to younger adult patients.”

Section 6 of the same label puts numbers on it. In the cardiovascular outcomes trial, hip and pelvis fractures were reported in 2.4 percent (17 of 703) of Wegovy-treated patients aged 75 and older versus 0.6 percent (4 of 663) on placebo, and in 1 percent (24 of 2,448) of female Wegovy patients versus 0.2 percent (5 of 2,424) on placebo [1]. In the separate MASH trial, fractures occurred in 4.4 percent of Wegovy patients versus 3.3 percent on placebo [1].

That is the single most concrete age-specific caution in the current GLP-1 labeling, and it is worth knowing about. Note what it is: an imbalance observed in trial subgroups and reported in the label. It is not a warning, a contraindication or an established causal effect.

It also sits against observational data pointing the other way, which is covered below.

How well do these drugs work after 65?

Tirzepatide

A post hoc analysis published online in Diabetes, Obesity and Metabolism in June 2026 pooled SURMOUNT-1 through SURMOUNT-5, including the three-year SURMOUNT-1 study, plus SURMOUNT-OSA and SUMMIT [5]. It compared participants 65 and older with those under 65.

Tirzepatide produced clinically meaningful weight reduction and favorable treatment differences in cardiometabolic risk factors and quality-of-life measures in the older group, broadly comparable to the younger group [5]. On safety, the pooled analysis found no clinically meaningful differences between tirzepatide and placebo in older adults across gastrointestinal tolerability, falls, fractures, depression outcomes, pancreatitis, and renal, hepatic, gallbladder and biliary adverse events [5].

The authors, most of whom work for Eli Lilly, concluded that the analysis “supports tirzepatide’s use in older adults when considering risks and benefits” [5]. Post hoc, sponsor-authored analyses deserve some skepticism, but the finding is consistent with the label language.

Semaglutide

A pooled analysis of three semaglutide phase 3a programs, published in 2025 to inform the evoke Alzheimer’s trials, included 3,529 participants aged 65 and older [6].

Adverse events occurred in 73.6 to 92.4 percent of participants 65 and older, versus 73.2 to 90.8 percent of the overall trial populations, so overall rates were similar [6]. Gastrointestinal disorders were the most common adverse events in both.

But discontinuation differed. Adverse events leading to permanent discontinuation appeared more frequent in participants 65 and older, 9.3 to 12.4 percent, versus 5.7 to 8.7 percent in the overall populations [6].

On weight, participants 65 and older on semaglutide had an estimated 3.8 percent weight loss at week 52 versus 0.1 percent on placebo [6]. That is a much smaller number than the headline STEP figures, but this pooled population included people with type 2 diabetes on lower doses and a lower average starting BMI, so it is not an apples-to-apples comparison with the 15 percent seen in STEP 1.

The practical reading: efficacy is broadly preserved, and tolerability is where age shows up.

The muscle question, honestly

This is the concern that gets raised most, and the evidence is more nuanced than either side of the argument usually admits.

The strongest single piece of evidence is a systematic review and meta-analysis published in Drugs in September 2026, conducted by a group including a WHO Collaborating Centre for the Epidemiology of Musculoskeletal Conditions and Ageing and the WHO’s Ageing and Life Course department [7]. It included 60 articles covering 1,250,717 individuals: 46 randomized trials, 13 real-world studies and one pharmacovigilance study, across semaglutide, liraglutide, exenatide, dulaglutide and tirzepatide.

Its three findings [7]:

Bone: no effect on bone mineral density at any site, and no effect on fractures at any site, when the most adjusted effect estimates were used.

Joints: no significant change in WOMAC pain, physical function or stiffness.

Muscle: a consistent decrease in lean body mass and fat-free mass. Across 28 comparisons, the standardized mean difference was -0.52 (95 percent confidence interval -0.8 to -0.23), with high heterogeneity. The effect was driven mainly by liraglutide and semaglutide against placebo, and it held in every sensitivity analysis.

The authors rated the certainty of the lean mass finding as low, noted the changes appeared largely related to the weight loss itself rather than the drug, and wrote that “whether these changes translate into clinically meaningful impairments in muscle function or physical performance remains uncertain” [7]. Their explanation is blunt: hardly any study measured strength, function or physical performance at all.

That gap is the real problem for older adults. Losing lean mass at 45 and losing it at 80 are different events, because the margin before crossing into frailty is different.

What about falls and fractures in the real world?

Here the observational data push back against the label observation.

A retrospective cohort using the TriNetX network from 2018 to 2025 included adults aged 65 and older with type 2 diabetes and a BMI of 25 or higher, comparing semaglutide or tirzepatide users with DPP-4 inhibitor users after 1:1 propensity score matching [8].

In 27,896 matched pairs, one-year femoral fracture was lower with semaglutide: 0.3 percent versus 0.5 percent, hazard ratio 0.488 (95 percent CI 0.367-0.649) [8]. In 12,808 matched pairs, femoral fracture was lower with tirzepatide: 0.2 percent versus 0.4 percent, hazard ratio 0.452 (0.280-0.729).

Falls were lower too: 3.6 percent versus 5.4 percent with semaglutide (HR 0.663) and 3.6 percent versus 5.7 percent with tirzepatide (HR 0.664) [8]. Fall reduction was consistent across subgroups, while fracture reduction was more pronounced in people with a BMI of 30 or higher.

A separate propensity-matched analysis of 56,142 pairs of women over 50 with osteoporosis found vertebral fracture in about 1.9 percent of GLP-1 users versus 4.3 percent of non-users (risk ratio 0.434) [9].

Both are observational, and both are vulnerable to healthy-user bias: people who get prescribed these drugs may already be more mobile and better engaged in care. But the direction is consistent, and it is the opposite of what the label’s 75-and-older observation would suggest. The honest answer is that this is unresolved.

Nutrition, and why it matters more after 65

A 2026 systematic review and meta-analysis in Obesity Science and Practice synthesized 19 randomized trials across the SURMOUNT, STEP, SCALE and OASIS programs [10]. It found:

• Daily energy intake declined 24.0 to 39.2 percent across drug classes, with model-estimated daily deficits reaching 1,200 kcal [10].
• Tirzepatide 15 mg was associated with a mean fat-free mass reduction of 1.60 kg, about 2.8 percent of body weight [10].
• Investigator-reported malnutrition occurred in only 0.12 percent of participants, but laboratory screening found total lymphocyte counts below 910 per microliter in 2.90 percent of active-therapy participants versus 1.77 percent in placebo arms, which the authors read as evidence that standard adverse event reporting underestimates nutritional risk [10].

They proposed a tiered stepped-care algorithm with baseline screening of albumin and total lymphocyte count, monitoring at weeks 12, 24 and 52, and defined intervention thresholds to prevent sarcopenia and frailty, “particularly in adults aged 65 years and older” [10].

That algorithm is a proposal by the authors. No professional society or regulator has adopted it. But it tells you what a careful prescriber might reasonably do, and it is worth raising.

Heart failure and other conditions that cluster with age

Heart failure with preserved ejection fraction is heavily concentrated in older adults, and it is the one heart failure type with dedicated randomized evidence for this drug class. An analysis of the STEP-HFpEF program published in the European Journal of Heart Failure in November 2025 examined whether semaglutide’s effect in obesity-related HFpEF varied across the age spectrum [11].

STEP-HFpEF and STEP-HFpEF DM together randomized 1,145 participants with obesity-related HFpEF to semaglutide 2.4 mg weekly or placebo, and the analysis split them into four age bands: under 55 (8.8 percent, n=101), 55 to 64, 65 to 74, and 75 and older [11]. Semaglutide improved disease-specific symptoms and physical function and reduced body weight across the whole age spectrum, with no significant heterogeneity between age groups, and the safety profile was consistent in older and younger patients [11].

That is a useful counterweight to the assumption that older patients have less to gain. It is also a single disease state, in a trial population selected for obesity-related HFpEF, and it does not generalize to every 78-year-old considering these drugs.

On the dementia question: semaglutide is being tested in early Alzheimer’s disease in the evoke and evoke+ trials, and a 2026 post hoc analysis of SELECT reported that semaglutide attenuated a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes [12]. A proteomic signature is a biomarker, not an outcome. The trials will answer the real question.

The Medicare problem

For many Americans over 65, none of the clinical debate matters as much as this: federal law has barred Medicare Part D from covering drugs used for weight loss since the benefit began [13].

That means on Medicare, one of these drugs is covered only for a non-weight indication: type 2 diabetes (Ozempic), cardiovascular risk reduction in people with established heart disease and obesity or overweight (Wegovy), or chronic kidney disease with type 2 diabetes (Ozempic injection) [13].

There is a workaround, and it is time-limited. CMS launched the Medicare GLP-1 Bridge on July 1, 2026, a nationwide demonstration that lets eligible Part D beneficiaries get certain obesity GLP-1 drugs at a flat $50 copay for a one-month supply, running through December 31, 2027 [13][14].

The covered list is narrower than most summaries suggest. Medicare’s own fact sheet names three products: Foundayo (orforglipron) tablets, Wegovy injection or tablets, and the Zepbound KwikPen only. The single-dose Zepbound pen and Zepbound vials are explicitly not covered, and neither are Ozempic, Mounjaro or Rybelsus [14].

Several mechanics are easy to miss. The drugs are furnished outside the Part D benefit payment flow, so the Part D deductible does not apply, none of the $50 counts toward true out-of-pocket costs, and there is no low-income subsidy on top of it. Manufacturer coupons and discount programs cannot be applied to a Bridge claim. And the Bridge covers these drugs only when they are prescribed for a weight-management indication; a GLP-1 covered under Part D for another indication stays with the Part D plan [13].

Separately, manufacturer copay savings cards for Ozempic and Wegovy exclude anyone enrolled in Medicare, Medicaid, TRICARE or VA coverage [13].

Prices and program rules in this area have changed repeatedly. Check current terms before making any decision based on cost.

Sources

1. WEGOVY (semaglutide) US Prescribing Information. Novo Nordisk. https://www.novo-pi.com/wegovy.pdf
2. OZEMPIC (semaglutide) US Prescribing Information. Novo Nordisk. https://www.novo-pi.com/ozempic.pdf
3. ZEPBOUND (tirzepatide) US Prescribing Information. Eli Lilly. https://uspl.lilly.com/zepbound/zepbound.html
4. MOUNJARO (tirzepatide) US Prescribing Information. Eli Lilly. https://uspl.lilly.com/mounjaro/mounjaro.html
5. Alfaris N, Kushner RF, Li J, et al. Tirzepatide for Obesity in Adults ≥65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials. Diabetes Obes Metab. Published online 2026 Jun 16. https://doi.org/10.1111/dom.70991
6. Sabbagh M, Boschini C, Cohen S, et al. Safety considerations of semaglutide in the potential treatment of Alzheimer’s disease: A pooled analysis of semaglutide in adults aged ≥65 years. Alzheimers Dement (N Y). 2025 May 6. https://doi.org/10.1002/trc2.70076
7. Beaudart C, Malréchauffé Y, van Heden S, et al. GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis. Drugs. 2026 Sep 12. https://doi.org/10.1007/s40265-026-02365-3
8. Chen HY, Wu JY, Chu YH, Chen TW, Huang CF. Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes. Osteoporos Int. 2026 Jul 11. https://doi.org/10.1007/s00198-026-08134-y
9. Stump K, Kelleher S, Aynaszyan S, Ricci S, Pazionis T. Investigating the Relationship Between GLP-1 Receptor Agonist Use and Incidence of Vertebral Fractures in Female Patients Aged Over 50 Years With Osteoporosis. Clin Spine Surg. 2026 Sep 1. https://doi.org/10.1097/BSD.0000000000002145
10. Ampofo E, Apprey C, Amoako M, Turkson FD. A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin Therapy. Obes Sci Pract. 2026 Sep 6. https://doi.org/10.1002/osp4.70188
11. Pandey A, Moroney M, Verma S, et al. Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme. Eur J Heart Fail. 2025 Nov. https://doi.org/10.1002/ejhf.70049
12. Jimenez-Mausbach M, Tijms BM, Paterson C, Refsgaard JC. Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial. Alzheimers Dement (Amst). 2026 Aug 8. https://doi.org/10.1002/dad2.70432
13. Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
14. Medicare. Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month. CMS Product No. 12234, June 2026. https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf
15. Mounjaro (tirzepatide) injection, US prescribing information, revised 8/2026. Eli Lilly and Company. https://uspl.lilly.com/mounjaro/mounjaro.html